Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus DESONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus DESONATE.
CAPEX vs DESONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Apply 0.05% cream, lotion, or ointment topically to affected skin twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal half-life is approximately 3-4 hours for desonide; clinically, this supports twice-daily dosing.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Renal (approximately 75% as metabolites, <5% unchanged) and fecal (approximately 25%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid